featured
Excess Long-Term Morbidity Limited but Not Eliminated by the Use of ABVD and Limited-Field Radiotherapy in Stage I–IIA Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy
J. Clin. Oncol 2022 Jan 25;[EPub Ahead of Print], I Lagerlöf, H Fohlin, G Enblad, B Glimelius, C Goldkuhl, M Palma, L Åkesson, I Glimelius, D MolinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.